Clinical trial
Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus
NCT00003487 · Burzynski Research Institute, Other · Terminated
Key facts
| NCT number | NCT00003487 |
|---|---|
| Title | Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus |
| Official title | Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Adenocarcinoma of the Esophagus |
| Lead sponsor | Burzynski Research Institute, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Esophagus |
| Intervention type | Drug |
| Interventions | Antineoplaston therapy (Atengenal + Astugenal) |
| Enrollment | 8 |
| Start date | May 30, 1996 |
| Primary completion | Apr 27, 2001 |
| Completion | Apr 27, 2001 |
| First posted | Jan 27, 2003 |
| Last update posted | May 14, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: